Journal
BIOMEDICINES
Volume 10, Issue 2, Pages -Publisher
MDPI
DOI: 10.3390/biomedicines10020274
Keywords
non-alcoholic fatty liver disease; non-alcoholic steatohepatitis; chronic liver disease; hepatoprotection; metabolic disorders
Categories
Funding
- Analytics and Devices Ltd. (St. Petersburg, Russia)
Ask authors/readers for more resources
This paper provides an update on the rapidly changing therapeutic landscape of non-alcoholic fatty liver disease (NAFLD). It highlights the major novel approaches to the treatment of this disease and reviews the current status of drug discovery and development pipeline, focusing on recent evidence from clinical trials.
Non-alcoholic fatty liver disease (NAFLD), or metabolic (dysfunction)-associated fatty liver disease (MAFLD), is characterized by high global incidence and prevalence, a tight association with common metabolic comorbidities, and a substantial risk of progression and associated mortality. Despite the increasingly high medical and socioeconomic burden of NAFLD, the lack of approved pharmacotherapy regimens remains an unsolved issue. In this paper, we aimed to provide an update on the rapidly changing therapeutic landscape and highlight the major novel approaches to the treatment of this disease. In addition to describing the biomolecules and pathways identified as upcoming pharmacological targets for NAFLD, we reviewed the current status of drug discovery and development pipeline with a special focus on recent evidence from clinical trials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available